Many clinical islet transplant programs have body mass index (BMI) and/or weight based thresholds for eligibility. Large subjects may require higher islet mass to reliably achieve insulin independence. However, for long term graft function and protection from hypoglycemia, data supporting a BMI based exclusion is lacking.

Methods: Subjects undergoing islet transplantation at a single center, between 1999 and 2017 were included. Graft survival as measured by C-peptide positivity from last CIT was compared between recipients with BMI<30 kg/m2 (n=237, 24.8±2.8 kg/m2) and BMI >30 kg/m2 (n=24, mean±SD 31.9±2.1 kg/m2) pre-transplant.

Results: Apart from BMI and weight (BMI<30 vs. BMI>30, 70.9±11.3 kg vs. 82.8±9.5 kg; P<0.05) there were no difference between groups in terms of baseline recipient characteristics, including in daily insulin dose (0.58±0.16 U/kg vs. 0.59±0.18 U/kg; P=0.34). Both groups received similar total number of islet infusions (2.4±0.9 and 2.3±0.6, p=0.6), total islet equivalents (1 053 022±471 532 vs. 1 182 498±366 368, P=0.19) and total islet equivalents per recipient body weight (15 208±6 373 IE/kg vs. 14 120±5 041 IE/kg, P=0.42). Long term C-peptide survival was not different between groups (P=0.18).

Conclusion: T1D patients with BMI>30 appear to have similar islet mass requirements and graft survival compared to those with BMI<30. This likely reflects careful selection of smaller (weight <90 kg), insulin sensitive (<0.6 U/kg) subjects with only class I obesity. Given the prevalence of obesity in T1D, future studies should evaluate the roles of obesity, weight and insulin sensitivity to ensure rational and equitable access to transplantation.

Disclosure

A. Lam: None. K.J. Potter: None. S. Forbes: None. S. Imes: None. A.J. Malcolm: None. A. Haqq: None. A. Shapiro: Consultant; Self; Viacyte, Inc., Protokinetix. P.A. Senior: Consultant; Self; Abbott, AstraZeneca. Research Support; Self; AstraZeneca, Prometic Life Sciences Inc., Novo Nordisk Inc., Sanofi. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc., Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; AstraZeneca, Merck & Co., Inc., Abbott. Research Support; Self; Viacyte, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.